OncoGenex's Synergy did not meet primary endpoint in Phase 3 trial OncoGenex Pharmaceuticals announced results from the Phase 3 SYNERGY trial. Top-line survival results indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in men with metastatic castrate-resistant prostate cancer, or CRPC, compared to docetaxel/prednisone alone. The adverse events observed were similar to custirsen's known adverse event profile.
News For OGXI From The Last 14 Days
Check below for free stories on OGXI the last two weeks.